放疗开放血脑屏障并与安罗替尼协同治疗胶质母细胞瘤
本研究通过临床前研究探讨放疗联合安罗替尼治疗胶质母细胞瘤(GBM)的价值。安罗替尼通过抑制JAK3/STAT3通路抑制恶性胶质瘤细胞生长并诱导凋亡,诱导G2/M期阻滞并增强放疗敏感性;放疗下调claudin-5削弱血脑屏障,使安罗替尼在中枢神经系统的分布增加1.0-2.9倍。体内评估显示安罗替尼单药或联合放疗有效且安全,作者认为该联合方案可能成为新诊断GBM有前景的治疗选择。
要点
- 安罗替尼通过抑制JAK3/STAT3通路抑制恶性胶质瘤细胞生长并诱导凋亡,且不依赖于MGMT表达。
- 安罗替尼诱导恶性胶质瘤细胞G2/M期阻滞并增强其对放疗的敏感性。
- 放疗下调claudin-5削弱血脑屏障,使安罗替尼在中枢神经系统的分布增加1.0-2.9倍。
核心结论
- 作者发现安罗替尼通过下调JAK3/STAT3轴发挥抗癌活性,单药或联合放疗均有效。
- 作者认为安罗替尼联合放疗可能成为新诊断胶质母细胞瘤有前景的临床治疗选择。
研究设计与样本
- 本研究为临床前研究,采用HPLC-MS/MS评估安罗替尼在血液和脑样本中的浓度。
- 体外实验采用细胞增殖实验、流式细胞术和集落形成实验。
- 体内实验评估安罗替尼单药或联合放疗对胶质母细胞瘤治疗的价值。
- 采用蛋白质印迹、免疫组织化学和免疫荧光染色探讨潜在机制。
主要发现
- 安罗替尼有效抑制JAK3/STAT3通路,抑制恶性胶质瘤细胞生长并诱导凋亡,且不依赖于MGMT表达。
- 安罗替尼诱导恶性胶质瘤细胞G2/M期阻滞,并使恶性胶质瘤细胞对放疗敏感。
- 放疗下调claudin-5并削弱血脑屏障,使安罗替尼在中枢神经系统的分布增加1.0-2.9倍。
- 体内实验中安罗替尼抑制肿瘤生长(PCNA)、抑制肿瘤微血管增殖(CD31)并缓解瘤内缺氧(HIF 1α)。
- 体内评估显示安罗替尼单药或联合放疗有效且安全。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) has a poor prognosis and lacks effective treatment. Anlotinib is a multitargeted receptor tyrosine kinase inhibitor (TKI) that may have anti-tumor activity in the central nervous system (CNS). This study aimed to determine the therapeutic value of radiotherapy combined with anlotinib in GBM via preclinical research. METHODS: HPLC-MS/MS was used to assess the concentration of anlotinib in blood and brain samples. Cell proliferation assays, flow cytometry, and colony formation assays were performed in vitro. The potential value of anlotinib or in combination with radiotherapy for GBM treatment was estimated in vivo. Western blotting, immunohistochemistry, and immunofluorescent staining were performed to determine the underlying mechanism. RESULTS: Anlotinib effectively inactivated the JAK3/STAT3 pathway to inhibit growth and induce apoptosis in malignant glioma cells (MGCs) independent of MGMT expression. Meanwhile, anlotinib induces MGCs G2/M arrest and sensitizes MGCs to radiation. Radiation down-regulates claudin-5 and weakens the blood-brain barrier (BBB), which contributes to the increased distribution of anlotinib in the CNS by 1.0-2.9 times. Anlotinib restrains tumor growth (PCNA), inhibits tumor microvascular proliferation (CD31), and alleviated intratumor hypoxia (HIF 1α) in vivo. Anlotinib alone or in combination with radiation is effective and safe in vivo evaluation. CONCLUSIONS: We discovered that anlotinib, the original small molecule antiangiogenesis TKI, down-regulates JAK3/STAT3 axis with anti-cancer activity alone or in combination with radiation. Anlotinib combined with radiotherapy might be a promising treatment for newly diagnosed GBM in the clinic.
引用
- Li PJ, Lai SZ, Jin T, et al. Radiotherapy opens the blood-brain barrier and synergizes with anlotinib in treating glioblastoma. Radiother Oncol. 2023. PMID: 36963438. doi:10.1016/j.radonc.2023.109633
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。